|Awarded On||November 02, 2011|
|Title||T-Cell Therapy After Hematopoietic Stem Cell Transplantation|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Laurence Cooper|
|Cancer Sites||Leukemia, Lymphoma|
Patients with cancerous B cells (non-Hodgkin lymphoma, small lymphocytic lymphoma, follicular lymphoma, and mantle cell lymphoma) that have relapsed or are resistant to therapies are at high risk of death. To control disease progression, these patients undergo autologous hematopoietic stem-cell transplantation (HSCT) enabling high doses of chemotherapy to be administered with concomitant rescue of bone marrow function upon infusion of their peripheral blood-derived stem cells (hematopoietic stem cells, HSC). Despite this intensive therapy, patients with active disease at time of HSCT have a survival of less than 20% due to a relapse in tumor burden. We seek to improve the outcome by employin...